CMS Bureau Francis Lefebvre has advised the shareholders of Finesco, the sole shareholder of Scomedica, a leading French healthcare contract sales organisation, for the contribution of their shares to Apricus Bio, an American pharmaceutical company listed on the NASDAQ market.
CMS Bureau Francis Lefebvre announced today that it advised the shareholders of Finesco-Scomedica, a leading French healthcare contract sales organisation, for the contribution of all of their outstanding shares to Apricus Biosciences Inc., an American pharmaceutical company listed on the NASDAQ market.
Under the terms of the share contribution agreement, Finesco shareholders will contribute to Apricus Bio 100% of the outstanding common stock of Finesco in exchange for newly issued shares of Apricus Bio common stock valued at €7 million (around $8.8 million). If Scomedica achieves certain revenue milestones during 2012, the Finesco shareholders could receive all of an additional issue of new shares worth up to €1.8 million (around $2.3 million) in the first quarter of 2013. Finesco and Scomedica will become wholly-owned subsidiaries of Apricus Bio.
Finesco/Scomedica advisors (France):
CMS Bureau Francis Lefebvre (Benoit Provost and Thomas Bortoli)
Finesco/Scomedica advisors (USA):
Kilpatrick Townsend & Stockton LLP (Richard Cicchillo and David Eaton)
Apricus Bio advisors (France):
Salans (Jean-Marc Grosperrin and Stéphane Jaffrain).
For more nformation, please contact: